109 related articles for article (PubMed ID: 16319324)
1. Monitoring of pulmonary function in Pompe disease: a muscle disease with new therapeutic perspectives.
van der Ploeg AT
Eur Respir J; 2005 Dec; 26(6):984-5. PubMed ID: 16319324
[No Abstract] [Full Text] [Related]
2. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.
Raben N; Fukuda T; Gilbert AL; de Jong D; Thurberg BL; Mattaliano RJ; Meikle P; Hopwood JJ; Nagashima K; Nagaraju K; Plotz PH
Mol Ther; 2005 Jan; 11(1):48-56. PubMed ID: 15585405
[TBL] [Abstract][Full Text] [Related]
3. Enzyme replacement therapy for infantile-onset pompe disease: curse or cure?
Willems J; Petros A; Brierley J
Neurology; 2008 Jul; 71(5):380-1. PubMed ID: 18663187
[No Abstract] [Full Text] [Related]
4. Comparative investigation of alpha-glucosidase activity in leucocytes and skeletal muscle of patients with Morbus Pompe.
Didt L; Winkler M; Bührdel P; Bormann M; Böhme HJ; Hofmann E
Z Med Lab Diagn; 1988; 29(1):7-11. PubMed ID: 3129881
[No Abstract] [Full Text] [Related]
5. [Two autopsy cases of adult-type acid maltase deficiency with vacuolation of cerebral arterial walls].
Matsuoka Y; Hirayama M; Senda Y; Matsui T
Rinsho Shinkeigaku; 1985 Jan; 25(1):39-45. PubMed ID: 3922655
[No Abstract] [Full Text] [Related]
6. Nosology of lysosomal glycogen storage diseases without in vitro acid maltase deficiency. Delineation of a neonatal form.
Verloes A; Massin M; Lombet J; Grattagliano B; Soyeur D; Rigo J; Koulischer L; Van Hoof F
Am J Med Genet; 1997 Oct; 72(2):135-42. PubMed ID: 9382133
[TBL] [Abstract][Full Text] [Related]
7. Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy.
van der Beek NA; Hagemans ML; van der Ploeg AT; Reuser AJ; van Doorn PA
Acta Neurol Belg; 2006 Jun; 106(2):82-6. PubMed ID: 16898258
[TBL] [Abstract][Full Text] [Related]
8. Mutations in the acid alpha-glucosidase gene (M. Pompe) in a patient with an unusual phenotype.
Anneser JM; Pongratz DE; Podskarbi T; Shin YS; Schoser BG
Neurology; 2005 Jan; 64(2):368-70. PubMed ID: 15668445
[TBL] [Abstract][Full Text] [Related]
9. Acid maltase deficiency in adolescence: report of an unusual case.
Olguntürk R; Bilgiç A; Cağlar M; Sinangil F
Turk J Pediatr; 1982; 24(2):115-9. PubMed ID: 6214067
[No Abstract] [Full Text] [Related]
10. Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail.
Kikuchi T; Yang HW; Pennybacker M; Ichihara N; Mizutani M; Van Hove JL; Chen YT
J Clin Invest; 1998 Feb; 101(4):827-33. PubMed ID: 9466978
[TBL] [Abstract][Full Text] [Related]
11. Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating.
Kroos M; Pomponio RJ; van Vliet L; Palmer RE; Phipps M; Van der Helm R; Halley D; Reuser A;
Hum Mutat; 2008 Jun; 29(6):E13-26. PubMed ID: 18425781
[TBL] [Abstract][Full Text] [Related]
12. [Childhood acid maltase deficiency. A case report].
Higashi Y; Shirabe T; Yasuda T; Inoue S; Sawayama T
Rinsho Shinkeigaku; 1988 Jan; 28(1):83-91. PubMed ID: 3133150
[No Abstract] [Full Text] [Related]
13. Biopsy-proven alpha-glucosidase deficiency with normal lymphocyte enzyme activity.
Whitaker CH; Felice KJ; Natowicz M
Muscle Nerve; 2004 Mar; 29(3):440-2. PubMed ID: 14981745
[TBL] [Abstract][Full Text] [Related]
14. Complete correction of acid alpha-glucosidase deficiency in Pompe disease fibroblasts in vitro, and lysosomally targeted expression in neonatal rat cardiac and skeletal muscle.
Pauly DF; Johns DC; Matelis LA; Lawrence JH; Byrne BJ; Kessler PD
Gene Ther; 1998 Apr; 5(4):473-80. PubMed ID: 9614571
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II.
Sun B; Zhang H; Franco LM; Young SP; Schneider A; Bird A; Amalfitano A; Chen YT; Koeberl DD
Mol Ther; 2005 Jan; 11(1):57-65. PubMed ID: 15585406
[TBL] [Abstract][Full Text] [Related]
16. Impaired performance of skeletal muscle in alpha-glucosidase knockout mice.
Hesselink RP; Gorselink M; Schaart G; Wagenmakers AJ; Kamphoven J; Reuser AJ; Van Der Vusse GJ; Drost MR
Muscle Nerve; 2002 Jun; 25(6):873-83. PubMed ID: 12115977
[TBL] [Abstract][Full Text] [Related]
17. Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intravenous injection with a modified adenoviral vector expressing hGAA.
Xu F; Ding E; Migone F; Serra D; Schneider A; Chen YT; Amalfitano A
J Gene Med; 2005 Feb; 7(2):171-8. PubMed ID: 15515143
[TBL] [Abstract][Full Text] [Related]
18. Pompe disease: a review of the current diagnosis and treatment recommendations in the era of enzyme replacement therapy.
Katzin LW; Amato AA
J Clin Neuromuscul Dis; 2008 Jun; 9(4):421-31. PubMed ID: 18525427
[TBL] [Abstract][Full Text] [Related]
19. [Severe form of juvenile type II glycogenosis in a compound-heterozygous boy (Tyr-292--> Cys/Arg-854-->Stop)].
Castro-Gago M; Eirís-Puñal J; Rodríguez-Núñez A; Pintos-Martínez E; Benlloch-Marín T; Barros-Angueira F
Rev Neurol; 1999 Jul 1-15; 29(1):46-9. PubMed ID: 10528311
[TBL] [Abstract][Full Text] [Related]
20. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 36-1986. A 29-year-old woman with slowly progressive proximal-muscle weakness.
N Engl J Med; 1986 Sep; 315(11):694-701. PubMed ID: 3092049
[No Abstract] [Full Text] [Related]
[Next] [New Search]
